Board

▼ Reasons for appointment

Isao Teshirogi became Representative Director and President in 2008. He has actively pushed forward with global research and development and expansion of global business to achieve the Third Medium-Term Business Plan and secured a medium- to long-term profit foundation. After achieving the quantitative targets of “Shionogi Growth Strategy 2020 (SGS2020),” formulated in FY2014, he updated the quantitative targets in October 2016 and also achieved these targets ahead of schedule. In 2020, he started a new Medium-Term Business Plan “Shionogi Transformation Strategy 2030 (STS2030),” that includes the Company’s vision toward 2030, “Building Innovation Platforms to Shape the Future of Healthcare,” and has vigorously moved forward the business transformation with the aim of achieving further growth. He is also promoting the approval and the filing of an application for the approval of COVID-19 drugs and vaccines, respectively, as a pharmaceutical company that strives to counter infectious diseases. 

Attended all 12 Board of Directors meetings of FY2022.

▼ Reasons for appointment

Since her appointment as a Director of the Company in June 2015, Takuko Sawada has been responsible for business execution of the Corporate Strategy Division as Senior Vice President of the Corporate Strategy Division and as a Senior Executive Officer. She also moved Medium-Term Business Plan Shionogi Growth Strategy 2020 (SGS2020) forward, and played a central role in formulating the update of SGS2020 in October 2016. She became Vice President in April 2018 and has been supervising the Integrated Disease Care Division, Corporate Strategy Division, Pharmaceutical Commercial Division and DX promotion Division to achieve the new Medium-Term Business Plan “Shionogi Transformation Strategy 2030 (STS2030)” from April 2020. She has been in charge of supervising management from a higher standpoint as Director and Vice Chairperson since July 2022. 

Attended all 12 Board of Directors meetings of FY2022.

▼ Reasons for appointment

Keiichi Ando has practical experience as a corporate executive at a financial institution and broad insight on finance. He also coordinated the extremely difficult adjustments between the national government and the governments of Osaka Prefecture and Osaka City for the airport management business of Kansai, which was then at a crossroads, and his experience and insight built the foundation of Kansai Airports, which plays a leading role in the current Kansai economy. At the Company’s Board of Directors meetings, he presents many questions and opinions from the perspective of risk management and the use of assets that are important management resources. He also provides appropriate advice on budget planning and management and capital policies, including investments, while, as chair of the Board, taking into account the timeliness and appropriateness of the proposals. Thus, he recognizes the corporate responsibility we should fulfill and makes management decisions with an emphasis on objectivity and impartiality, without bias in favor of corporate executives or specific interested parties. 

Attended all 12 Board of Directors meetings of FY2022.

▼ Reasons for appointment

Hiroshi Ozaki has abundant practical experience and wide-ranging knowledge in corporate management and organizational management as a manager of a company based in Kansai. He is also the former chairman of the Osaka Chamber of Commerce and Industry, and during his tenure promoted the economic growth of Osaka and Kansai based on the medium-term plan he developed, as well as focusing on promoting the life science industry. At the Company’s Board of Directors meetings, he points out problems appropriately and provides many supportive comments, such as advice on business and marketing, including production and distribution, and raising concerns regarding alliances. Accordingly, he makes management decisions with an emphasis on objectivity and neutrality based on his extensive experience and knowledge. 

Attended all 12 Board of Directors meetings of FY2022.

▼ Reasons for appointment

Fumi Takatsuki has extensive experience and professional insight from her position as an attorney in international corporate law and in legal response relating to the Chinese life science and healthcare industry. Although she has not been involved in company management in any capacity other than as an outside director in the past, at the Company’s Board of Directors meetings, she points out problems and provides sound advice on issues that need to be considered, particularly concerning business expansion in Asia, including China, from the perspective of international corporate legal affairs. Accordingly, she makes fair management decisions from a global perspective, giving priority to legal compliance and social norms.

Attended all 12 Board of Directors meetings of FY2022.

▼ Reasons for appointment

Takaoki Fujiwara has extensive practical experience and a wide range of knowledge as a manager of a group of companies engaged in urban transport, real estate, and entertainment, mainly in the Kansai area. He has served as the Company’s Corporate Auditor since June 2018. At the Board of Directors and Board of Corporate Auditors meetings, he provides appropriate advice mainly on compliance and human resource management, as well as auditing the appropriateness of management decisions and execution of duties by the directors from a broad perspective. We expect him to make appropriate and adequate management decisions in the 159th Term. 

Attended all 12 Board of Directors meetings of FY2022.

Attended all 11 Board of Corporate Auditors meetings of FY2022.

▼ Reasons for appointment

Akira Okamoto has served as General Manager of administrative units, including the Business Support Center and the Personnel Department, and is well-versed in corporate management. He provides appropriate recommendations and advice on the management decisions and execution of duties by the Directors from an independent point of view as a Corporate Auditor, leveraging his experience in being involved in enhancing the Company’s corporate governance and upgrading and operating the internal control system as General Manager of the Internal Control Department.

Accordingly, we judge that he has the appropriate character and insight to perform the duties of a corporate auditor.

Attended all 12 Board of Directors meetings of FY2022.

Attended all 11 Board of Corporate Auditors meetings of FY2022.

▼ Reasons for appointment

Mr. Ikuo Kato has served as General Manager of the Development Research Laboratories of the Company and as Representative Director and President and Chairman of subsidiary. He is not only well-versed in research and development, but has insight on corporate management. As Representative Director and President and Chairman of the subsidiary, he offers comments as necessary to the Shionogi Group’s management, and in our judgement, he provides appropriate recommendations and advice on management decisions and execution of duties from a neutral point of view as a corporate auditor. 

Attended all 12 Board of Directors meetings of FY2022.

Attended all 11 Board of Corporate Auditors meetings of FY2022.

▼ Reasons for appointment

Tsuguoki Fujinuma has professional expertise in finance and accounting. He has held many important posts, including Chairman and President of the Japanese Institute of Certified Public Accountants, and has extensive experience and broad insight as outside director and outside corporate auditor of a wide range of companies. Although he has not been involved in company management in any capacity other than as an outside executive in the past, he performs higher-quality audits of the Company from the perspective of finance and accounting based on his extensive experience as a certified public accountant. He also provides appropriate advice mainly from the finance, accounting, and sustainability viewpoint at the Board of Directors and Board of Corporate Auditors meetings.

Accordingly, we expect him to reflect his experience in the audits of the Company concerning the appropriateness of the management decisions and execution of duties by the directors from an independent point of view as an outside corporate auditor. 

Attended all 12 Board of Directors meetings of FY2022.

Attended all 11 Board of Corporate Auditors meetings of FY2022.

▼ Reasons for appointment

Shuichi Okuhara is qualified as a certified public accountant and has professional expertise in finance and accounting. We believe that he will be able to carry out audits suitable for the continually changing business environment based on his experience as Board member of Nippon Venture Capital Co., Ltd. in a social environment that places importance on peer or cross-industrial partnerships. 

Attended all 12 Board of Directors meetings of FY2022.

Attended all 11 Board of Corporate Auditors meetings of FY2022.

▼ Reasons for appointment

Yoriko Goto has professional expertise in finance and accounting as a certified public accountant and extensive management experience and broad insight through her service as Chairperson of the Board of Deloitte Tohmatsu Group and Deloitte Touche Tohmatsu LLC, among others. As she also serves as outside director of a financial institution, we believe that she will audit the Company from the finance, accounting, and management viewpoint.

Accordingly, we expect her to reflect her experience in the audits of the Company concerning the appropriateness of the management decisions and execution of duties by the directors from an independent point of view as an outside corporate auditor.